Unknown

Dataset Information

0

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.


ABSTRACT: Many different aberrations in the Anaplastic Lymphoma Kinase (ALK) were found to be oncogenic drivers in several cancers including neuroblastoma (NB), therefore ALK is now considered a critical player in NB oncogenesis and a promising therapeutic target. The ALK-inhibitor crizotinib has a limited activity against the various ALK mutations identified in NB patients. We tested: the activity of the novel ALK-inhibitor X-396 administered alone or in combination with Targeted Liposomes carrying ALK-siRNAs (TL[ALK-siRNA]) that are active irrespective of ALK gene mutational status; the pharmacokinetic profiles and the biodistribution of X-396; the efficacy of X-396 versus crizotinib treatment in NB xenografts; whether the combination of X-396 with the TL[ALK-siRNA] could promote long-term survival in NB mouse models. X-396 revealed good bioavailability, moderate half-life, high mean plasma and tumor concentrations. X-396 was more effective than crizotinib in inhibiting in vitro cell proliferation of NB cells and in reducing tumor volume in subcutaneous NB models in a dose-dependent manner. In orthotopic NB xenografts, X-396 significantly increased life span independently of the ALK mutation status. In combination studies, all effects were significantly improved in the mice treated with TL[ALK-siRNA] and X-396 compared to mice receiving the single agents. Our findings provide a rational basis to design innovative molecular-based treatment combinations for clinical application in ALK-driven NB tumors.

SUBMITTER: Di Paolo D 

PROVIDER: S-EPMC4745691 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.

Di Paolo Daniela D   Yang D D   Pastorino Fabio F   Emionite Laura L   Cilli Michele M   Daga Antonio A   Destafanis Elisa E   Di Fiore Annarita A   Piaggio Francesca F   Brignole Chiara C   Xu Xiaobao X   Liang Chris C   Gibbons James J   Ponzoni Mirco M   Perri Patrizia P  

Oncotarget 20151001 30


Many different aberrations in the Anaplastic Lymphoma Kinase (ALK) were found to be oncogenic drivers in several cancers including neuroblastoma (NB), therefore ALK is now considered a critical player in NB oncogenesis and a promising therapeutic target. The ALK-inhibitor crizotinib has a limited activity against the various ALK mutations identified in NB patients. We tested: the activity of the novel ALK-inhibitor X-396 administered alone or in combination with Targeted Liposomes carrying ALK-s  ...[more]

Similar Datasets

| S-EPMC3818140 | biostudies-literature
| S-EPMC3045808 | biostudies-literature
| S-EPMC6625372 | biostudies-literature
| S-EPMC8554663 | biostudies-literature
| S-EPMC3219872 | biostudies-literature
| S-EPMC8470592 | biostudies-literature
| S-EPMC5601691 | biostudies-literature
| S-EPMC5923368 | biostudies-literature
2011-07-07 | E-GEOD-22771 | biostudies-arrayexpress
| PRJNA352077 | ENA